Australia's most trusted
source of pharma news
Tuesday, 24 March 2026
Posted 23 March 2026 AM
The onslaught of PBAC rejections is taking a human toll beyond patients, with distress levels also rising for Australian pharma employees, according to industry coach and best-selling author, Paula Fenwick.
She said while patients have the most to lose, pharma teams are also feeling the fallout - from resubmission pressures and a sense of failure to job security fears. For companies, every rejection or deferral ties up capital and strains budgets.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.